Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Becotatug Vedotin and Pucotenlimab in Recurrent Head and Neck Squamous Cell Carcinoma
NCT07589049Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin, pucotenlimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Sun Yat-sen University. Planned start May 2026; status: not yet recruiting.
02
Drugs
becotatug vedotinpucotenlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07589049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07589049.